SCHEMBL21660442

SCHEMBL21660442

Cc1ccc2c(c1)N(CC(C)N(C)C)c1ccccc1S2

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 8/20 0.78
▸ HTR1A P08908 8/20 0.78
▸ CHRM2 P08172 7/20 0.78
▸ CHRM1 P11229 7/20 0.78
▸ ADRA1A P35348 7/20 0.78
▸ OPRM1 P35372 7/20 0.78
▸ DRD3 P35462 7/20 0.78
▸ KCNH2 Q12809 7/20 0.78
▸ ADRA2A P08913 6/20 0.78
▸ DRD1 P21728 6/20 0.78
▸ CYP1A2 P05177 6/20 0.78
▸ LMNA P02545 5/20 0.78
▸ SLC6A2 P23975 5/20 0.78
▸ SLC6A4 P31645 5/20 0.78
▸ DRD2 P14416 5/20 0.78
▸ PTGS1 P23219 4/20 0.78
▸ ADRA2B P18089 4/20 0.78
▸ ADRA2C P18825 4/20 0.78
▸ CHRM3 P20309 4/20 0.78
▸ HTR2A P28223 4/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Promethazine SCHEMBL4700 0.89 CYP2D6 (1.00) CYP2D6HTR1ACHRM2CHRM1ADRA1A
Promethazine SCHEMBL29372077 0.89 CYP2D6 (1.00) CYP2D6HTR1ACHRM2CHRM1ADRA1A
Promethazine SCHEMBL26777 0.89 CYP2D6 (1.00) CYP2D6HTR1ACHRM2CHRM1ADRA1A
(S)-Promethazine SCHEMBL2900853 0.89 CYP2D6 (1.00) CYP2D6HTR1ACHRM2CHRM1ADRA1A
Promethazine SCHEMBL5501515 0.87 LMNA (1.00) CYP2D6HTR1ACHRM2CHRM1ADRA1A
Promethazine SCHEMBL5425141 0.87 LMNA (1.00) CYP2D6HTR1ACHRM2CHRM1ADRA1A
Promethazine SCHEMBL41904 0.87 LMNA (1.00) CYP2D6HTR1ACHRM2CHRM1ADRA1A
Promethazine SCHEMBL29390401 0.87 LMNA (1.00) CYP2D6HTR1ACHRM2CHRM1ADRA1A
Promethazine SCHEMBL2962420 0.87 LMNA (1.00) CYP2D6HTR1ACHRM2CHRM1ADRA1A
Promethazine SCHEMBL27559626 0.87 LMNA (1.00) CYP2D6HTR1ACHRM2CHRM1ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10869933-B2 Oligomer-phenothiazine conjugates NEKTAR THERAPEUTICS (US) 2020-12-22 — — US disclosed
US-20200038517-A1 OLIGOMER-PHENOTHIAZINE CONJUGATES NEKTAR THERAPEUTICS (US) 2020-02-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10869933-B2 Oligomer-phenothiazine conjugates HTT, MAPT, SLCO1B3 CYP2D6 283/4885HTR1A 518/4885CHRM2 973/4885
US-20200038517-A1 OLIGOMER-PHENOTHIAZINE CONJUGATES HTT, MAPT, SLCO1B3 CYP2D6 283/4885HTR1A 518/4885CHRM2 973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback